RCPT: Receptos looks like its been successful at accessing improved cost of capital to fund its clinical programs; formed out of Apoptos after the latter ran into issues, the company repositioned itself in 2011, got its S1P program into the clinic, in-licensed an Abbott mAb, and is up 2x+ since that time.